AgomAb Therapeutics NV · NASDAQ (us_market)
Healthcare · Biotechnology · Belgium
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-03-02$16.21 RISE2026-04-08$9.85 PEAK2026-05-05$12.50 64d | -39.2% 37d | Missed | Missed | — | — | +26.9% 27d | Missed |
No scored news yet for a sentiment trend.
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences: ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activ
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) ---- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second
AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,577,230 covering the composition of matter for AGMB-447. The company said AGMB-447 is an investigational inhaled, lung-restricted small […]
AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,577,230 covering the composition of matter for AGMB-447. The company said AGMB-447 is an investigational inhaled, lung-restricted small […]
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company’s investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic P
Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No.
Leerink Partners analyst Thomas Smith initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Outperform rating and announces Price Target of $36.
JP Morgan analyst Anupam Rama initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $32.
Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.
Morgan Stanley analyst Judah Frommer initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $28.
European equities traded in the US as American depositary receipts were rising on Wednesday morning,
European equities traded in the US as American depositary receipts were rising on Wednesday morning,
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common sha
Agomab (AGMB) priced 12.5M shares at $16.00, inside the $15.00-$17.00 target range. JPMorgan, Morgan Stanley, Leerink and Kempen are acting as joint book running managers for the offering. Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need.Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful inves
Agomab (AGMB) priced 12.5M shares at $16.00, inside the $15.00-$17.00 target range. JPMorgan, Morgan Stanley, Leerink and Kempen are acting as joint book running managers for the offering. Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need.Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful inves
Seven IPOs and six SPACs priced this week, with five IPOs and five SPACs submitted filings. Read more here.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AGMB | +0.54% | -30.60% | — | — |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -2.43% | -24.88% | — | — |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 1.46M | $15.30M | 0.00% | New | 2026-03-31 |
| DEShaw | quant | 15.3K | $160.77K | 0.00% | New | 2026-03-31 |
| TwoSigma | quant | 14.2K | $149.39K | 0.00% | New | 2026-03-31 |